Theriva Biologics
Rockville
About Theriva Biologics
Theriva Biologics is an innovative clinical-stage immuno-oncology company that is dedicated to the development of oncolytic viruses. These specialized viruses are engineered to target and overcome the protective barriers that solid tumors create, enabling them to selectively infect and destroy cancer cells. By harnessing the power of the immune system and the unique properties of oncolytic viruses, Theriva aims to provide a groundbreaking approach to cancer treatment that enhances therapeutic efficacy while minimizing damage to surrounding healthy tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $46.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nysemkt:TOVX
- Website: therivabio.com
- Phone: (734) 332-7800
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/theriva-biologics-16455 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.